ASTRO guideline endorses trimodal therapy and 55 Gy in 20 fractions for bladder cancer
ASTRO recommends trimodal therapy as an alternative to cystectomy in selected muscle-invasive bladder cancer and supports 55 Gy in 20 fractions.
Tag
High relevance
Total laryngectomy improved local control over chemoradiotherapy in selected advanced laryngeal cancer
Surgery provided substantially better local control in T3–T4a N0–N1 laryngeal cancer, while disease-specific survival remained similar and CRT preserved laryngeal function in 79%.
Clinicians underestimated urinary and bowel symptoms after prostate radiotherapy
HYPO-RT-PC showed persistently poor agreement between patient- and clinician-reported toxicity, particularly for urinary and bowel symptoms.
Open-face masks improved head and neck RT experience without compromising setup accuracy
In the randomized OPEN trial, SGRT-supported open masks maintained setup accuracy while reducing distress and improving treatment experience.
Adding CyberKnife SBRT to lenvatinib and tislelizumab tracked with longer survival in HCC
IPTW-weighted response was 71.1% versus 37.6%, with median survival 23.0 versus 15.6 months after adding SBRT.
MR-guided prostate re-irradiation achieved high early control but accumulating GU toxicity
Failure-free survival was 96.6% at 12 months, while grade 3 GU toxicity increased to 12.5% by one year.
One-week HDR brachytherapy shortened cervical cancer treatment without higher reported toxicity
Compressing three HDR brachytherapy fractions into one week shortened overall treatment time and increased early complete response without improving survival.
Personalized ctDNA predicted outcomes throughout treatment for localized soft tissue sarcoma
Personalized ctDNA was detected in 85% at baseline and remained independently prognostic before treatment, after radiotherapy and after surgery.
All-in-one emergency radiotherapy delivered treatment in a median 25 minutes
An integrated CT-linac workflow delivered emergency radiotherapy in 24.7 minutes, with symptom relief in nearly 90% of patients.
DEGRO updates radiotherapy recommendations for Merkel cell carcinoma
DEGRO supports postoperative radiotherapy within eight weeks while expanding hypofractionated options for frail and selected Merkel cell carcinoma patients.
Greater use of radical radiotherapy tracked with improved lung cancer survival
Radical radiotherapy use nearly doubled while five-year lung cancer-specific survival rose from 21.9% to 33.1% across Northern Ireland.
Breast re-irradiation achieved 84.2% five-year recurrence-free survival with 3.9% grade 3 toxicity
After resection of ipsilateral recurrence, five-year locoregional recurrence-free survival was 84.2%, while grade 3 late toxicity was 3.9%.
Moderately hypofractionated regional nodal irradiation had 6.4% three-year lymphedema
With 42.56 Gy in 16 fractions, three-year lymphedema was 6.4%, with no new events through five years.
ESTRO and ILROG define modern technical standards for total skin electron therapy
ESTRO consensus recommendations establish standardized dose, delivery, shielding and quality-assurance principles for total skin electron therapy.
p16-guided mucosal de-intensification showed strong control in head and neck unknown primary
Reduced ipsilateral mucosal irradiation produced 90% five-year survival in p16-positive unknown-primary disease, with no out-of-field mucosal or neck failures.